Siddiqui M T, Garrity E R, Martinez R, Husain A N
Department of Pathology, Loyola University Medical Center, Maywood, Illinois 60153, USA.
Mod Pathol. 1996 Mar;9(3):320-8.
Lung transplantation is an accepted mode of therapy for selected patients with end-stage lung disease. Their long-term survival is mainly limited by chronic rejection, i.e., bronchiolitis obliterans (BO), which represents a fibrosing inflammatory process of the terminal and respiratory bronchioles, leading to progressive small airway obstruction. To evaluate its development, and associated irreversible allograft dysfunction, we retrospectively studied the histological and clinical data from nine patients who developed BO, and nine matched control patients. A total of 152 serial transbronchial biopsies (87 from patients with BO; 65 from the control group) were studied using immunohistochemical stains, with antibodies to laminin, desmin, fibronectin, collagen IV, collagen III, and vimentin. The staining with anti-collagen IV antibody was the most productive and in eight of the nine patients with BO demonstrated early focal bronchiolar basement membrane damage, manifested by thickening and subsequent splitting and duplication. This was seen in association with the second episode and onward of clinically significant episodes of acute cellular rejection which occurred 7 to 12 months posttransplant. The larger airways were unaffected. The histological onset of BO exhibited varying degrees of obstruction of the bronchioles with no detectable basement membrane staining. The control patients failed to demonstrate these findings. The other immunohistochemical stains used were found to be noncontributory. We conclude that the usage of anti-collagen IV on lung allograft biopsies demonstrates the sequential changes of bronchiolar basement membrane disruption in lung allograft recipients who have multiple episodes of clinically significant acute cellular rejection and later develop BO.
肺移植是终末期肺病特定患者可接受的治疗方式。他们的长期生存主要受慢性排斥反应限制,即闭塞性细支气管炎(BO),这是一种终末细支气管和呼吸性细支气管的纤维化炎症过程,导致进行性小气道阻塞。为评估其发展及相关的不可逆移植肺功能障碍,我们回顾性研究了9例发生BO的患者及9例匹配的对照患者的组织学和临床数据。共对152次系列经支气管活检标本(87份来自BO患者;65份来自对照组)使用抗层粘连蛋白、抗结蛋白、抗纤连蛋白、抗IV型胶原、抗III型胶原和抗波形蛋白抗体进行免疫组织化学染色研究。抗IV型胶原抗体染色效果最佳,9例BO患者中有8例显示早期局灶性细支气管基底膜损伤,表现为增厚,随后分裂和重复。这与移植后7至12个月发生的第二次及以后的具有临床意义的急性细胞排斥发作相关。较大气道未受影响。BO的组织学发病表现为细支气管不同程度的阻塞,未检测到基底膜染色。对照患者未出现这些表现。发现使用的其他免疫组织化学染色无贡献。我们得出结论,在肺移植活检中使用抗IV型胶原可显示在发生多次具有临床意义的急性细胞排斥且随后发生BO的肺移植受者中细支气管基底膜破坏的连续变化。